Ruggero Dittadi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ruggero Dittadi has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
Paolo Carraro
Osped Angelo, Lab Med Unit, Dept Clin Pathol, ULSS 3 Serenissima, I-30122 Mestre Venice, Italy
7 shared publications- Aline Sueli Coelho Fabricio
Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
4 shared publications Marco Migliardi
European Ligand Assay Society (ELAS)-Italia , Milan , Italy
4 shared publications- Massimo Gion
IRCCS San Camillo Hospital , Venice , Italy
4 shared publications Haleh Afshar
Laboratory Medicine Unit, Ospedale dell’Angelo, ULSS 3 Serenissima, Mestre, Italy
3 shared publicationsIsabella Bertoli
Laboratory Medicine Unit, Ospedale dell’Angelo, ULSS 3 Serenissima, Mestre, Italy
3 shared publications
Latest Publications
- 21 September 2026
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
Thyroglobulin antibody in differentiated thyroid cancer: international laboratory practice survey and the case for a dual-threshold model
Objectives: Anti-thyroglobulin antibodies (TgAb) have a dual role during the follow-up of differentiated thyroid cancer (DTC): they may interfere with thyroglobulin (Tg) immunoassays and also serve as surrogate biomarkers of disease status. However, laboratory practices for TgAb measurement and reporting remain poorly standardised. We conducted an international survey to characterize current laboratory approaches and identify opportunities for harmonization. Methods: A structured questionnaire was distributed to 120 laboratory medicine centres performing Tg and TgAb testing. The survey collected information on analytical platforms, TgAb reporting practices, positivity and interference thresholds, interference assessment strategies, and the interpretation of longitudinal TgAb changes. Results were analysed descriptively. Results: Fifty-one centres from six European countries participated (response rate, 42 %). Most laboratories (88 %) measured Tg and TgAb using assays from the same manufacturer. Marked heterogeneity was observed in quantitative TgAb reporting, definition of pathological TgAb concentrations, and thresholds considered indicative of potential Tg assay interference. Although more than half of the laboratories reported having defined an interference threshold, only two (4 %) implemented and explicitly reported separate thresholds for thyroid autoimmunity and Tg assay interference. Structured interference investigations were uncommon (26 %) and relied mainly on recovery testing, whereas predefined delta-check criteria for longitudinal TgAb interpretation were used by only 8 % of centres. Conclusions: Current laboratory practice for TgAb testing in DTC is highly heterogeneous and may contribute to inconsistent interpretation of Tg results. A dual-threshold reporting model that clearly distinguishes the diagnostic threshold for thyroid autoimmunity from the analytical threshold indicating potential Tg assay interference promote harmonization. Routine support for longitudinal TgAb interpretation, including serial trend reporting, represents an additional opportunity for laboratory specialists to enhance the management of patients with DTC.
- 21 September 2026
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
Thyroglobulin antibody in differentiated thyroid cancer: international laboratory practice survey and the case for a dual-threshold model
Objectives: Anti-thyroglobulin antibodies (TgAb) have a dual role during the follow-up of differentiated thyroid cancer (DTC): they may interfere with thyroglobulin (Tg) immunoassays and also serve as surrogate biomarkers of disease status. However, laboratory practices for TgAb measurement and reporting remain poorly standardised. We conducted an international survey to characterize current laboratory approaches and identify opportunities for harmonization. Methods: A structured questionnaire was distributed to 120 laboratory medicine centres performing Tg and TgAb testing. The survey collected information on analytical platforms, TgAb reporting practices, positivity and interference thresholds, interference assessment strategies, and the interpretation of longitudinal TgAb changes. Results were analysed descriptively. Results: Fifty-one centres from six European countries participated (response rate, 42 %). Most laboratories (88 %) measured Tg and TgAb using assays from the same manufacturer. Marked heterogeneity was observed in quantitative TgAb reporting, definition of pathological TgAb concentrations, and thresholds considered indicative of potential Tg assay interference. Although more than half of the laboratories reported having defined an interference threshold, only two (4 %) implemented and explicitly reported separate thresholds for thyroid autoimmunity and Tg assay interference. Structured interference investigations were uncommon (26 %) and relied mainly on recovery testing, whereas predefined delta-check criteria for longitudinal TgAb interpretation were used by only 8 % of centres. Conclusions: Current laboratory practice for TgAb testing in DTC is highly heterogeneous and may contribute to inconsistent interpretation of Tg results. A dual-threshold reporting model that clearly distinguishes the diagnostic threshold for thyroid autoimmunity from the analytical threshold indicating potential Tg assay interference promote harmonization. Routine support for longitudinal TgAb interpretation, including serial trend reporting, represents an additional opportunity for laboratory specialists to enhance the management of patients with DTC.
- 5 December 2024
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 62 (3) , 222-223
Interference in immunoassay
- 5 December 2024
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 62 (3) , 222-223
Interference in immunoassay
- 18 March 2024
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 61 (4) , 327-328
Interferences in immunoassay: An estimate based on ‘real-world’ experience
- 18 March 2024
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 61 (4) , 327-328
Interferences in immunoassay: An estimate based on ‘real-world’ experience
- Open Access
- 1 October 2023
- Published by AME Publishing Company in Journal of Laboratory and Precision Medicine
- Vol. 8, 30
Identification of interferences in free thyroxin assay—establishment of acceptable recovery limits for the dilution test
One of the simplest and most effective methods to verify the presence of analytical interferences in immunoassays is the dilution test. Use of this test is generally not recommended in free T4 (fT4) immunoassays, but it has been previously successfully used for the detection of interferences. The aim of this study was to confirm the data previously published and to determine an acceptable range for recovery, beyond which the presence of interference can be considered probable. fT4 were measured with Access Free T4 assay (Beckman Coulter Inc., Brea, CA, USA). After preliminary evaluation of this method’s performance in a dilution test of 13 samples of patients with different binding capacities, the acceptable range of recovery of the dilution test was evaluated using 121 analytically and clinically plausible specimens within the measurement range of the assay. Moreover, 44 cases were evaluated with inconsistent results among the measured thyroid hormones. The acceptability range (2.5th–97.5th percentile) of recovery was between 77.4% and 121.7%. In 23 of the 44 suspected cases evaluated, the result of dilution showed recoveries within the established acceptability range, and the value of fT4 was also confirmed on another analytical platform (Liason XL). In the 21 cases where the recoveries were outside the acceptability range, the concentrations measured on Liaison XL were instead markedly different from the Access method and showed probable interferences. In conclusion, it has been verified that the Access fT4 method allows to obtain an excellent recovery at the dilution test, at least up to the 1/10 dilution. The reference ranges established for the acceptability of recovery under non-interference conditions allow to identify a possible analytical interference in a simple and reproducible way.
- 1 October 2023
- Published by AME Publishing Company in Journal of Laboratory and Precision Medicine
- Vol. 8, 30
Open AccessIdentification of interferences in free thyroxin assay—establishment of acceptable recovery limits for the dilution test
One of the simplest and most effective methods to verify the presence of analytical interferences in immunoassays is the dilution test. Use of this test is generally not recommended in free T4 (fT4) immunoassays, but it has been previously successfully used for the detection of interferences. The aim of this study was to confirm the data previously published and to determine an acceptable range for recovery, beyond which the presence of interference can be considered probable. fT4 were measured with Access Free T4 assay (Beckman Coulter Inc., Brea, CA, USA). After preliminary evaluation of this method’s performance in a dilution test of 13 samples of patients with different binding capacities, the acceptable range of recovery of the dilution test was evaluated using 121 analytically and clinically plausible specimens within the measurement range of the assay. Moreover, 44 cases were evaluated with inconsistent results among the measured thyroid hormones. The acceptability range (2.5th–97.5th percentile) of recovery was between 77.4% and 121.7%. In 23 of the 44 suspected cases evaluated, the result of dilution showed recoveries within the established acceptability range, and the value of fT4 was also confirmed on another analytical platform (Liason XL). In the 21 cases where the recoveries were outside the acceptability range, the concentrations measured on Liaison XL were instead markedly different from the Access method and showed probable interferences. In conclusion, it has been verified that the Access fT4 method allows to obtain an excellent recovery at the dilution test, at least up to the 1/10 dilution. The reference ranges established for the acceptability of recovery under non-interference conditions allow to identify a possible analytical interference in a simple and reproducible way.
- Open Access
- 28 February 2023
- Published by SAGE Publications in The International Journal of Biological Markers
- Vol. 38 (1) , 61-71
Overordering of tumor marker for outpatients revealed by performance indicators and the impact of a health policy intervention: An observational study using administrative records
Purpose: The overuse of laboratory tests contributes to impair health systems effectiveness, tumor markers (TMs) being a paradigmatic example. In the present study we applied indicators of TMs appropriateness developed from administrative datasets to appraise regionwide overordering in the clinical practice. Patients and methods: TMs ordered to outpatients in the Veneto Region over 6 years were obtained from the eletronic Outpatients’ Records of Diagnostic and Therapeutic Procedures. TMs orders were examined as aggregated data or stratified according to disease codes, gender, age, and requests per patient. TMs recommended only for specific malignancies were examined using epidemiological data obtained from Veneto Tumor Registry. Results: A total of 5,821,251 TMs were ordered in 4,382,159 patients over 6 years. Overall, 3,252,389 (55.9%) TMs were ordered without appropriate disease codes (ranging from 77.0% for PSA to 17.5% for CA15.3). TM orders declined over 6 years (−13.4%), with a noticeable reduction of orders without appropriate disease codes (−21.3%). Orders decreased sharply from 2015 to 2016, after the enactment of a national Decree-Law aimed at improving appropriateness, and remained stable thereafter. However, the rate of inappropriate TMs requests still remained elevated (44.4%) in the last year of observation, with orders of TMs being much higher than expected on the basis of prevalence and incidence figures of specific malignancies. Conclusions: Indicators developed from administrative datasets were effective in assessing the overordering of TMs and the impact of interventions to improve appropriateness. The developed indicators could be considered for other diagnostic tests.
- 28 February 2023
- Published by SAGE Publications in The International Journal of Biological Markers
- Vol. 38 (1) , 61-71
Open AccessOverordering of tumor marker for outpatients revealed by performance indicators and the impact of a health policy intervention: An observational study using administrative records
Purpose: The overuse of laboratory tests contributes to impair health systems effectiveness, tumor markers (TMs) being a paradigmatic example. In the present study we applied indicators of TMs appropriateness developed from administrative datasets to appraise regionwide overordering in the clinical practice. Patients and methods: TMs ordered to outpatients in the Veneto Region over 6 years were obtained from the eletronic Outpatients’ Records of Diagnostic and Therapeutic Procedures. TMs orders were examined as aggregated data or stratified according to disease codes, gender, age, and requests per patient. TMs recommended only for specific malignancies were examined using epidemiological data obtained from Veneto Tumor Registry. Results: A total of 5,821,251 TMs were ordered in 4,382,159 patients over 6 years. Overall, 3,252,389 (55.9%) TMs were ordered without appropriate disease codes (ranging from 77.0% for PSA to 17.5% for CA15.3). TM orders declined over 6 years (−13.4%), with a noticeable reduction of orders without appropriate disease codes (−21.3%). Orders decreased sharply from 2015 to 2016, after the enactment of a national Decree-Law aimed at improving appropriateness, and remained stable thereafter. However, the rate of inappropriate TMs requests still remained elevated (44.4%) in the last year of observation, with orders of TMs being much higher than expected on the basis of prevalence and incidence figures of specific malignancies. Conclusions: Indicators developed from administrative datasets were effective in assessing the overordering of TMs and the impact of interventions to improve appropriateness. The developed indicators could be considered for other diagnostic tests.
- 10 March 2022
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 60 (6) , e136-e137
Biological variation and reference change value as decision criteria in clinical use of tumor biomarkers. Are they really useful?
Article Biological variation and reference change value as decision criteria in clinical use of tumor biomarkers. Are they really useful? was published on March 10, 2022 in the journal Clinical Chemistry and Laboratory Medicine (CCLM) (volume 0, issue 0).
- 10 March 2022
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 60 (6) , e136-e137
Biological variation and reference change value as decision criteria in clinical use of tumor biomarkers. Are they really useful?
Article Biological variation and reference change value as decision criteria in clinical use of tumor biomarkers. Are they really useful? was published on March 10, 2022 in the journal Clinical Chemistry and Laboratory Medicine (CCLM) (volume 0, issue 0).
- Open Access
- 14 February 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (2) , 483
Harmonization of Determination of SARS-CoV-2 Antibodies: Is It Always Possible?
A WHO standard was prepared with the aim of harmonizing assays detecting antibodies against SARS-CoV-2, but the issue is currently being debated. We re-evaluated a previously studied set of cases (108 specimens of 48 patients and 60 specimens of 20 vaccinated subjects, collected after 14 days from the first dose and 14 days and 3 months after a second dose of the Comirnaty BNT162b2 vaccine), calculating the ratios between the results of two methods (SARS-CoV-2 IgG anti-RBD, SNIBE, and anti-SARS-CoV-2 QuantiVac ELISA IgG, Euroimmun). In the vaccinated subjects, the ratios of the results between methods according to the WHO standard were relatively dispersed, but the harmonization results were good. On the other hand, in patient samples, the variability between tests was very high, and the harmonization was unsatisfactory (median ratios between methods 2.23, 10th–90th percentile: 1.1–5.6). Interestingly, in patient samples, the harmonization depends on the time from the onset of symptoms and greatly improves after 6 months since the diagnosis. Forty patient specimens and thirty-one of the vaccinated subjects after the second dose were also evaluated with a third method (Access SARS-CoV-2 IgG (1st IS), Beckman Coulter), obtaining a similar trend. We can conclude that the actual effectiveness of harmonization between methods may vary depending on the scenario in which they will be used.
- 14 February 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (2) , 483
Open AccessHarmonization of Determination of SARS-CoV-2 Antibodies: Is It Always Possible?
A WHO standard was prepared with the aim of harmonizing assays detecting antibodies against SARS-CoV-2, but the issue is currently being debated. We re-evaluated a previously studied set of cases (108 specimens of 48 patients and 60 specimens of 20 vaccinated subjects, collected after 14 days from the first dose and 14 days and 3 months after a second dose of the Comirnaty BNT162b2 vaccine), calculating the ratios between the results of two methods (SARS-CoV-2 IgG anti-RBD, SNIBE, and anti-SARS-CoV-2 QuantiVac ELISA IgG, Euroimmun). In the vaccinated subjects, the ratios of the results between methods according to the WHO standard were relatively dispersed, but the harmonization results were good. On the other hand, in patient samples, the variability between tests was very high, and the harmonization was unsatisfactory (median ratios between methods 2.23, 10th–90th percentile: 1.1–5.6). Interestingly, in patient samples, the harmonization depends on the time from the onset of symptoms and greatly improves after 6 months since the diagnosis. Forty patient specimens and thirty-one of the vaccinated subjects after the second dose were also evaluated with a third method (Access SARS-CoV-2 IgG (1st IS), Beckman Coulter), obtaining a similar trend. We can conclude that the actual effectiveness of harmonization between methods may vary depending on the scenario in which they will be used.
- Open Access
Harmonization of SARS CoV-2 antibodies determination. Is it really possible?
The WHO standard was prepared with the aim of harmonizing assays detecting antibodies against SARS CoV-2. The aspect of the harmonization of the assays is to date under debate. We re-evaluated a previously studied set of cases (108 specimens of 48 patients and 60 specimens of 20 vaccinated subjects, collected after 14 days from the first dose, 14 days and 3 months after a second dose of the Comirnaty BNT162b2 vaccine), calculating the ratios between the results of two methods (SARS-CoV-2 IgG anti-RBD, SNIBE and anti-SARS-CoV-2 QuantiVac ELISA IgG, Euroimmun). In the vaccinated subjects the ratios of the results between methods according to the WHO standard were relatively dispersed, but the harmonization results good. On the other hand, in patient samples the variability between tests was very high and the harmonization was unsatisfactory (median ratios between methods 2.23, 10th-90th percentile: 1.1-5.6). Interestingly, in patient samples the harmonization depends on the time from the onset of symptoms, and greatly improves after 6 months from the diagnosis. 40 patient specimens and 31 of vaccinated subjects after the second dose were evaluated also with a third method (Access SARS-CoV-2 IgG (1st IS), Beckman Coulter), obtaining a similar trend. We can conclude that the actual effectiveness of harmonization between methods may vary depending on the scenario in which they will be used.
Open AccessHarmonization of SARS CoV-2 antibodies determination. Is it really possible?
The WHO standard was prepared with the aim of harmonizing assays detecting antibodies against SARS CoV-2. The aspect of the harmonization of the assays is to date under debate. We re-evaluated a previously studied set of cases (108 specimens of 48 patients and 60 specimens of 20 vaccinated subjects, collected after 14 days from the first dose, 14 days and 3 months after a second dose of the Comirnaty BNT162b2 vaccine), calculating the ratios between the results of two methods (SARS-CoV-2 IgG anti-RBD, SNIBE and anti-SARS-CoV-2 QuantiVac ELISA IgG, Euroimmun). In the vaccinated subjects the ratios of the results between methods according to the WHO standard were relatively dispersed, but the harmonization results good. On the other hand, in patient samples the variability between tests was very high and the harmonization was unsatisfactory (median ratios between methods 2.23, 10th-90th percentile: 1.1-5.6). Interestingly, in patient samples the harmonization depends on the time from the onset of symptoms, and greatly improves after 6 months from the diagnosis. 40 patient specimens and 31 of vaccinated subjects after the second dose were evaluated also with a third method (Access SARS-CoV-2 IgG (1st IS), Beckman Coulter), obtaining a similar trend. We can conclude that the actual effectiveness of harmonization between methods may vary depending on the scenario in which they will be used.
- Open Access
- 18 September 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (9) , 1709
Antibodies against SARS-CoV-2 Time Course in Patients and Vaccinated Subjects: An Evaluation of the Harmonization of Two Different Methods
The time course of antibodies against SARS-CoV-2 is not yet well elucidated, especially in people who underwent a vaccination campaign. In this study, we measured the antibodies anti-S1 and anti-RBD with two different methods, both in patients and in vaccinated subjects. One hundred and eight specimens from 48 patients with COVID-19 (time from the onset of symptoms from 3 to 368 days) and 60 specimens from 20 vaccinated subjects (collected after 14 days from the first dose, 14 days and 3 months after a second dose of Comirnaty) were evaluated. We used an ELISA method that measured IgG against anti-Spike 1, and a chemiluminescence immunoassay that measured IgG anti-RBD. In the patients, the antibodies concentrations tended to decline after a few months, with both the methods, but they persisted relatively high up to nearly a year after the symptoms. In the vaccinated subjects, the antibodies were already detectable after the first dose, but after the booster, they showed a significant increase. However, the decrease was rapid, given that 3 months after the second vaccination, they were reduced to less than a quarter. The conversion of the results into BAU units improves the relationship between the two methods. However, in the vaccinated subjects, there was no evidence of proportional error after the conversion, while in the patients, the difference between the two methods remained significant.
- 18 September 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (9) , 1709
Open AccessAntibodies against SARS-CoV-2 Time Course in Patients and Vaccinated Subjects: An Evaluation of the Harmonization of Two Different Methods
The time course of antibodies against SARS-CoV-2 is not yet well elucidated, especially in people who underwent a vaccination campaign. In this study, we measured the antibodies anti-S1 and anti-RBD with two different methods, both in patients and in vaccinated subjects. One hundred and eight specimens from 48 patients with COVID-19 (time from the onset of symptoms from 3 to 368 days) and 60 specimens from 20 vaccinated subjects (collected after 14 days from the first dose, 14 days and 3 months after a second dose of Comirnaty) were evaluated. We used an ELISA method that measured IgG against anti-Spike 1, and a chemiluminescence immunoassay that measured IgG anti-RBD. In the patients, the antibodies concentrations tended to decline after a few months, with both the methods, but they persisted relatively high up to nearly a year after the symptoms. In the vaccinated subjects, the antibodies were already detectable after the first dose, but after the booster, they showed a significant increase. However, the decrease was rapid, given that 3 months after the second vaccination, they were reduced to less than a quarter. The conversion of the results into BAU units improves the relationship between the two methods. However, in the vaccinated subjects, there was no evidence of proportional error after the conversion, while in the patients, the difference between the two methods remained significant.
- Open Access
Antibodies anti-SARS-CoV2 time-course in patients and vaccinated subjects: an evaluation of the harmonization of two different methods
The time-course of antibodies anti SARS-CoV2 is not yet well elucidated, especially in people who underwent a vaccination campaign. In this study we measured antibodies anti-S1 and anti-RBD with two different methods both in patients and in vaccinated subjects. 108 specimens from 48 patients diagnosed as COVID-19 affected (time from the onset of symptoms from 3 to 368 days) and 60 specimens from 20 vaccinated subjects (collected after 14 days from the first dose, 14 days and 3 months after a second dose of Comirnaty) were evaluated. We used an ELISA method that measure IgG against anti-Spike 1 and a chemiluminescence immunoassays that measure IgG anti-RBD. In the patients, antibodies concentrations tend to decline after a few months with both methods, but persist relatively high up to nearly a year after symptoms. In vaccinated subjects, antibodies were already detectable after the first dose, but after the booster they show a significant increase. However, the decrease is rapid, given that after 3 months after the second vaccination they are reduced to less than a quarter. The conversion of the results into BAU units improves the relationship between the two methods. However, in vaccinated subjects there was no evidence of proportional error after the conversion, while in the patients the difference between the two methods remained significant.
Open AccessAntibodies anti-SARS-CoV2 time-course in patients and vaccinated subjects: an evaluation of the harmonization of two different methods
The time-course of antibodies anti SARS-CoV2 is not yet well elucidated, especially in people who underwent a vaccination campaign. In this study we measured antibodies anti-S1 and anti-RBD with two different methods both in patients and in vaccinated subjects. 108 specimens from 48 patients diagnosed as COVID-19 affected (time from the onset of symptoms from 3 to 368 days) and 60 specimens from 20 vaccinated subjects (collected after 14 days from the first dose, 14 days and 3 months after a second dose of Comirnaty) were evaluated. We used an ELISA method that measure IgG against anti-Spike 1 and a chemiluminescence immunoassays that measure IgG anti-RBD. In the patients, antibodies concentrations tend to decline after a few months with both methods, but persist relatively high up to nearly a year after symptoms. In vaccinated subjects, antibodies were already detectable after the first dose, but after the booster they show a significant increase. However, the decrease is rapid, given that after 3 months after the second vaccination they are reduced to less than a quarter. The conversion of the results into BAU units improves the relationship between the two methods. However, in vaccinated subjects there was no evidence of proportional error after the conversion, while in the patients the difference between the two methods remained significant.